Mechanism of action
Retatrutide (LY3437943) is a single-molecule agonist of three G-protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). In the published pharmacology, GLP-1R activation is associated with glucose-dependent insulin secretion and reduced appetite signalling via hypothalamic satiety circuits; GIPR activation potentiates insulin secretion and is discussed as a possible attenuating factor for nausea; GCGR activation stimulates hepatic lipid oxidation and increases energy expenditure and thermogenesis in preclinical models. The peptide carries a fatty-acid modification that slows elimination. Coskun et al. (Cell Metabolism 2022, Table 1) report geometric mean half-lives of 134 to 165 hours across six single-subcutaneous-administration cohorts of healthy adults. Roughly six days, or 144 hours, is an approximate study reference rather than an exact universal mean; the 2023 Jastreboff trial was phase 2, not a TRIUMPH phase 3 trial. The receptor pharmacology of the discovery compound is described in vitro and in animal models by Coskun et al. (Cell Metabolism 2022).
State of evidence
The published evidence spans preclinical characterization and randomized clinical trials through phase 3. Coskun et al. (Cell Metabolism 2022) describe the discovery of LY3437943, including receptor pharmacology, animal models and early clinical proof-of-concept data. Two randomized phase 2 trials followed: Jastreboff et al. (NEJM 2023) examined body-weight changes over 48 weeks in adults with obesity, while Rosenstock et al. (Lancet 2023) examined HbA1c and body weight in type 2 diabetes versus placebo and dulaglutide. In the published phase 3 TRANSCEND-T2D-1 trial, Bajaj et al. (Lancet 2026) randomized 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone. Over 40 weeks, HbA1c, the primary endpoint, and body weight, a key secondary endpoint, improved versus placebo. Gastrointestinal adverse events were common. These findings are distinct from the ongoing cardiovascular and kidney outcomes trial TRIUMPH-Outcomes (NCT06383390), which addresses different endpoints and longer follow-up. A completed glycaemic trial does not resolve every long-term benefit or risk, and clinical study material is not interchangeable with a research product. The cited trial reports do not establish a particular product's authorization or therapeutic equivalence.
Questions about the research
- What is retatrutide being investigated for in research?
- Retatrutide is studied in metabolic research on obesity and type 2 diabetes, with published randomized phase 2 trials and phase 3 TRANSCEND-T2D-1 data on glycaemic control and body weight. The separate ongoing TRIUMPH-Outcomes trial examines cardiovascular and kidney outcomes. Mechanistic work investigates simultaneous activation of the GIP, GLP-1 and glucagon receptors.
- What is the current state of evidence on retatrutide?
- Published evidence includes preclinical and early clinical characterization (Coskun et al., 2022), two randomized phase 2 trials in 2023 and the placebo-controlled phase 3 TRANSCEND-T2D-1 trial published in 2026. The latter enrolled 537 adults with type 2 diabetes for 40 weeks and found improvements in HbA1c and body weight, with common gastrointestinal adverse events. Longer-term outcomes remain a separate research question, and these findings do not establish authorization or equivalence of a research product.
Sources
- Jastreboff et al., NEJM 2023DOI: 10.1056/NEJMoa2301972PMID: 37366315
- Coskun et al., Cell Metab 2022DOI: 10.1016/j.cmet.2022.07.013PMID: 35985340
- Rosenstock et al., Lancet 2023DOI: 10.1016/S0140-6736(23)01053-XPMID: 37385280
- ClinicalTrials.gov NCT06383390 (TRIUMPH-Outcomes, Phase 3)
- Bajaj et al., TRANSCEND-T2D-1 randomized phase 3 trial, Lancet 2026DOI: 10.1016/s0140-6736(26)00967-0PMID: 42250575
